Leukemia & Lymphoma Projects



With evolving technologies and emerging treatment options, this call is focused on defining subgroups of patients with a given diagnosis, understanding the role and improving detection of minimal residual disease (MRD) in hematological malignancies and using this information to guide treatment intervention. LLS has formed a partnership with Celgene to create the first set of such grants that will build the foundation of this new initiative.

Termini IISPV

1- Declaration of interest: IISPV’s deadline: May 15, 2014 (europa@iispv.cat). LOI: May 23th, 2014. Full proposal: IISPV’s deadline: Application July 9th, 2014.

Termini Oficial

1. Official’s deadline: June 3rd, 2014. Letter of Intent (LoI): LoIs will summarize the proposed research and indicate which topic is most appropriate. LOIs will be reviewed for responsiveness to the grant outline, and approved (ore rejected) by LLS staff shortly after the time of submission. 


2. Full application:Official’s deadline: July 15th, 2014.


Estàs interessat?

Omple el següent formulari per rebre més informació: